|
Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study. |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche Pharma AG |
Research Funding - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche Pharma AG |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche Pharma AG |
Speakers' Bureau - GlaxoSmithKline |
Research Funding - Bristol-Myers Squibb (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
Honoraria - Meda Pharmaceuticals; Menarini; Novartis; Roche Pharma AG |
Consulting or Advisory Role - LEO Pharma; Meda Pharmaceuticals; Menarini; Novartis; Roche Pharma AG; Spirig Pharma AG |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche Pharma AG |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche Pharma AG |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche/Genentech; Ventana Medical Systems |
Research Funding - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst) |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Novartis; SOBI; VentiRx |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Bayer; Debiopharm Group; Merck Serono; SOBI |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche Pharma AG |
Consulting or Advisory Role - GlaxoSmithKline; Merck Sharp & Dohme; Roche Pharma AG |
Expert Testimony - Roche Pharma AG |
|
|
Leadership - Amgen; Bristol-Myers Squibb; Roche Pharma AG |
Honoraria - Bristol-Myers Squibb; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche Pharma AG |
Expert Testimony - Amgen; Bristol-Myers Squibb; Roche Pharma AG |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche Pharma AG |
|
|
Honoraria - Roche Pharma AG |
Research Funding - Bristol-Myers Squibb (Inst); LEO Pharma (Inst); Roche Pharma AG (Inst) |
|
|
Honoraria - GlaxoSmithKline; Roche Pharma AG |
Consulting or Advisory Role - Roche Pharma AG |
Research Funding - AstraZeneca (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Novartis; Roche Pharma AG |
|
|
Honoraria - Bristol-Myers Squibb; Merck; Roche Pharma AG |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche Pharma AG |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
Employment - Roche Pharma AG |
|
|
Employment - Roche Pharma AG |
Stock and Other Ownership Interests - Roche Pharma AG |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche Pharma AG |
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche Pharma AG |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche Pharma AG |